<DOC>
	<DOCNO>NCT02919696</DOCNO>
	<brief_summary>The purpose study determine safety study drug know abemaciclib native Chinese participant advance and/or metastatic cancer .</brief_summary>
	<brief_title>A Study Abemaciclib ( LY2835219 ) Native Chinese Participants With Advanced and/or Metastatic Cancers</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<criteria>The participant must histological cytological evidence cancer advance and/or metastatic , appropriate candidate experimental therapy judgment investigator , available standard therapy cease provide clinical benefit . Have presence measureable disease define Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) . Are native Chinese men woman . Have adequate organ function , include : Hematologic : Absolute neutrophil count ( ANC ) ≥1.5 x 109/Liters ( L ) , platelets ≥100 x 109/L , hemoglobin ≥9 gram per deciliter . Participants may receive erythrocyte transfusion achieve hemoglobin level platelet transfusion achieve platelet level discretion investigator ; however , initial study drug treatment must begin early day transfusion . Hepatic : Bilirubin ≤1.5 time upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ≤3.0 time ULN . Renal : Serum creatinine ≤1.2 milligrams per deciliter ( mg/dL ) males ≤1.0 mg/dL female . Have performance status ≤1 Eastern Cooperative Oncology Group ( ECOG ) scale . Recovered acute effect therapy ( treatment relate toxicity resolve baseline ) except residual alopecia . Have estimate life expectancy ≥12 week . Have receive previous therapy cancer ( include chemotherapy , radiotherapy , immunotherapy , investigational therapy ) within 21 day myelosuppressive agent 14 day nonmyelosuppressive agent prior receive study drug . Have acute leukemia relevant cancer discretion investigator . Females pregnant lactating . Participants consume drug food know inducer ( example , grapefruit juice , phenytoin , carbamazepine ) strong inhibitor CYP3A4 exclude Cycle 1 . Have history evidence central nervous system ( CNS ) malignancy metastasis . Screening asymptomatic participant without history CNS metastases require enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>CDK4/6 Inhibitor</keyword>
</DOC>